Eliot Moon
Child & Adolescent Psychiatry · Pasadena, CANPI 1821153743
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Lundbeck LLC at 48.1% of the total.
Across 39 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$320
- Sunovion Pharmaceuticals Inc.$207
- Takeda Pharmaceuticals U.S.A., Inc.$53
- Arbor Pharmaceuticals, Inc.$44
- Johnson & Johnson$40
Across 96 payments — averaging $5441.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$336K
- H. Lundbeck A S$69K
- Pfizer$60K
- Amgen$17K
- Sanofi US Services Inc.$13K
- Shire North American Group Inc$13K
- plus $15K from 4 others
What the payments were for
- Food & beverage$664100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 16 | $320 |
| Sunovion Pharmaceuticals Inc. | 15 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Johnson & Johnson | 2 | $40 |
How this compares
$664 in reported general payments places this provider in the 75th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $16,223 |
| Lurasidone Hcl | 12 | $6,626 |
| Aripiprazole | 17 | $6,251 |
| Bupropion XlBupropion Hcl | 145 | $2,427 |
| Vilazodone Hcl | 24 | $2,388 |
| Methylphenidate ErMethylphenidate Hcl | 46 | $1,849 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 12 | $1,739 |
| Ziprasidone Hcl | 21 | $1,706 |
| Oxcarbazepine | 11 | $1,608 |
| Lisdexamfetamine Dimesylate | 13 | $1,322 |
| Alprazolam | 120 | $1,267 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 36 | $1,163 |
| Lorazepam | 112 | $1,059 |
| Paliperidone ErPaliperidone | 11 | $925 |
| Diazepam | 53 | $800 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Pasadena
- Daryoush JamalPasadena$13K
- Linda WoodallPasadena$3K
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.